Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

Background: The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates PI3K signalling. Antibody-mediated inhibition of this ERBB2/ERBB3/PI3K axis has been a cornerstone of treatment for ERBB2-amplif...

Descripción completa

Detalles Bibliográficos

Publicado en:	Breast Cancer Research Vol. 21; no. 1
Autores principales:	Kennedy, Sean P., Han, Jeremy Z. R., Portman, Neil, Nobis, Max, Hastings, Jordan F., Murphy, Kendelle J., Latham, Sharissa L., Cadell, Antonia L., Miladinovic, Dushan, Marriott, Gabriella R., O'Donnell, Yolande E. I., Shearer, Robert F., Williams, James T., Munoz, Amaya Garcia, Cox, Thomas R., Watkins, D. Neil, Saunders, Darren N., Timpson, Paul, Lim, Elgene, Kolch, Walter
Formato:	research Journal Article
Publicado:	BioMed Central 3/21/2019
Acceso en línea:	Ver este registro en EBSCOhost